High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 701–800 of 960
Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis
Parvathaneni, V., Shukla, S. K., & Gupta, V. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_8 · Cited by 4
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01476-3 · Cited by 7
ISMP Medication Error Report Analysis
Cohen, M. R. (2006) · Hospital Pharmacy · doi:10.1177/001857870604101002 · Cited by 3
Novel therapy for idiopathic pulmonary fibrosis—How to evaluate the efficacy?
Azuma, A., & Usuki, J. (2008) · Respiratory Medicine CME · doi:10.1016/j.rmedc.2008.06.001 · Cited by 3
Systematic review of content and quality of idiopathic pulmonary fibrosis review articles
Milne, K. M., Chan, C., Fisher, J. H., de Boer, K., & Ryerson, C. J. (2018) · ERJ Open Research · doi:10.1183/23120541.00156-2018 · Cited by 3
Current Challenges and Future Perspectives
Rajagopalan, R., & Zhang, L. (2019) · CRC Press eBooks · doi:10.1201/9780429423772-6 · Cited by 3
Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?
Wolters, P. J. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00283.2009 · Cited by 3
“Using this approach, the authors ask whether inhibition of EMT of alveolar type II cells by N-acetylcysteine (NAC) could contribute to the apparent clinical benefit NAC provides in slowing the loss of lung function in IPF patients (1).”
BackgroundIdiopathic pulmonary fibrosis: the disease in search of its cause
Sharma, O. P. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000239545.17208.15 · Cited by 4
Beneficial Effect of N-acetylcysteine on Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Park, S. J., Pai, K. S., Kim, J. H., & Shin, J. I. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111025 · Cited by 3
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
Kropski, J. A., Lawson, W. E., & Blackwell, T. S. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201509-1789ed · Cited by 3
“In contrast to findings from the earlier IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N-acetylcysteine I Annual) study (4), the NAC versus placebo arms of the PANTHER trial (5) found no benefit to NAC treatment.”
ResultIs N-acetylcysteine effective in the treatment of pulmonary fibrosis?
Pulgar, A. J., & Gonzalo Labarca, T. (2016) · Medwave · doi:10.5867/medwave.2016.6555 · Cited by 3
Helou, D. G., & Crestani, B. (2024) · European Respiratory Journal · doi:10.1183/13993003.01954-2023 · Cited by 3
Magnesium, Zinc and Copper in Lung Fibrosis: A Narrative Review
Nechifor, M., Zamfir, C. L., & Galeş, C. (2025) · Medicina · doi:10.3390/medicina62010010 · Cited by 3
“In the case of IPF, several drugs such as Prednisone, Azathioprine, and N-Acetylcysteine (in monotherapy or in therapeutic combinations) have been recommended but have not been satisfactory [214].”
Azuma, A., & Richeldi, L. (2020) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2020.0005 · Cited by 2
Phase three clinical trials in idiopathic pulmonary fibrosis
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882299 · Cited by 2
“Despite the lack of a real placebo group for control and a substantial number of drop-outs (about 30% patients from each group) [21], NAC became a regular treatment for IPF along with prednisone and azathioprine, thus forming the so-called ‘triple therapy’.”
BackgroundFeshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, Y., & Liskina, I. V. (2021) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2021-29-3-5-23 · Cited by 2
The Importance of the Redox Modulation in the Prevention and Treatment of Chronic Pulmonary Diseases
Borrelli, E. (2022) · Biochemistry · doi:10.5772/intechopen.108887 · Cited by 2
Roles of antioxidants in the prevention and management of coronavirus disease 2019
Salem, M. A., Zayed, A., Merghany, R. M., & Ezzat, S. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95574-4.00020-2 · Cited by 2
Role of N-acetylcysteine and vitamin B complex in improving outcomes of corrosive ingestion
Elsobky, H. A., Elshanawany, S. M., Ghanem, M., & Atef, M. (2024) · Toxicology Research · doi:10.1093/toxres/tfad125 · Cited by 2
Stress oxydatif et BPCO. Rôle des infections. Prévention
Léophonte, P., Guérin, J. C., Lebas, F.-X., Liard, F., & Boulanger, P. (2006) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2005.12.006 · Cited by 2
Le traitement des fibroses pulmonaires idiopathiques
Dury, S. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71556-x · Cited by 2
Crestani, B., Marchand-Adam, S., Taillé, C., Borie, R., & Danel, C. J. (2010) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(10)70328-4 · Cited by 2
Diffuse Lung Disease: Classification and Evaluation
Collard, H. R., & King, T. E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_6 · Cited by 2
Survival after massive intentional overdose of paraquat.
Lalloo, U., & Ambaram, A. (2008) · PubMed · Cited by 2
Evaluation of bosentan for idiopathic pulmonary fibrosis
Swigris, J. J., & Brown, K. K. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.3.315 · Cited by 2
Ask the expert - diffuse interstitial lung disease
Costabel, U. (2007) · Breathe · doi:10.1183/18106838/breathe.4.2.165 · Cited by 2
“the IFIGENIA trial using high-dose NAC added to the recommended standard treatment with prednisone and azathioprine [7].”
BackgroundMethodSelf-citationHanda, T., & Azuma, A. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_9 · Cited by 2
Mécanismes physiopathologiques de la fibrose pulmonaire idiopathique
Crestani, B. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32326-x · Cited by 2
Varney, V., Salisbury, D., Parnell, H., Ratnatheepan, S., Nicholas, A., Quirke, G., Sumar, N., & Bansal, A. S. (2017) · Pharmacology & Pharmacy · doi:10.4236/pp.2017.83007 · Cited by 2
“This was shown to be improved by oral N-acetyl cysteine (NAC) which can generate glutathione, and led to the NAC clinical trials [7] [8].”
BackgroundTratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad
FLORENZANO, M., V, & C, F. R. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400287 · Cited by 3
Wilson, A. M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Hammond, M., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08090 · Cited by 3
Drug Therapy for Interstitial Lung Disease
Baughman, R. P., Costabel, U., & Lower, E. E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_7 · Cited by 2
Self-citationDevelopments in the management of idiopathic pulmonary fibrosis
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.7.0337 · Cited by 2
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 4
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00514-z · Cited by 3
Raghu, G. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00067306 · Cited by 2
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Cerri, S., Giovane, C. D., Balduzzi, S., Soncini, F., Sdanganelli, A., & Richeldi, L. (2013) · Clinical Investigation · doi:10.4155/cli.13.39 · Cited by 2
Current and Future Therapies for Idiopathic Pulmonary Fibrosis
Maher, T. M. (2011) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3182350bb4 · Cited by 2
Yamaguchi, M., Seto, T., Furuya, A., Edagawa, M., Shimamatsu, S., Toyozawa, R., Toyokawa, G., Nosaki, K., Hirai, F., Takenoyama, M., et al. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.08.011 · Cited by 2
Potential Alteration of Tumor Microenvironments by β-Mercaptoethanol
Click, R. E. (2020) · Future Oncology · doi:10.2217/fon-2020-0801 · Cited by 2
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Mohning, M. P., Swigris, J. J., & Olson, A. L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_2 · Cited by 2
Acetylcysteine in Pulmonary Fibrosis
Hull, J. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053493 · Cited by 2
BREAST IMPLANT SURFACE DEVELOPMENT
Lazenco, V., & Alicia, A. (2015) · Research Explorer (The University of Manchester) · Cited by 2
Health effects of quercetin : from mechanism to nutraceutical
Boots, A. W. (2006) · Research Publications (Maastricht University) · doi:10.26481/dis.20061221ab · Cited by 6
Wells, A. U., Richards, T. J., & Martínez, F. J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201107-1216ed · Cited by 2
The Pulmonary Arteries, Idiopathic Pulmonary Fibrosis, and Lung Transplantation
Chan, C. M., & Shorr, A. F. (2011) · CHEST Journal · doi:10.1378/chest.10-2400 · Cited by 2
Kardos, P. (2008) · Pharmazie in unserer Zeit · doi:10.1002/pauz.200800286 · Cited by 2
External validity of randomised controlled trials in idiopathic pulmonary fibrosis
Thomeer, M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00151305 · Cited by 2
Self-citationAirway Management in Critically Ill Patients
Al-Khafaji, A. H., & Cho, S. M. (2007) · CHEST Journal · doi:10.1378/chest.07-0624 · Cited by 3
COPD—pharmakologische Basisbehandlung und Zukunft der antiinflammatorischen Therapie
Watz, H., Bitter-Suermann, S., Kanniess, F., & MAGNUSSEN, H. (2006) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-006-1036-6 · Cited by 2
Corticosteroids May Worsen Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis
Fimognari, F. L., & Pastorelli, R. (2007) · CHEST Journal · doi:10.1378/chest.06-2659 · Cited by 2
Zhang, S.-M., Huang, M.-Z., Wang, Y.-W., Wang, X.-F., Ding, Y., Li, J. Q., Zou, X.-M., & Ma, C. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108946 · Cited by 2
Sharata, E. E., Abdelnaser, M., Bakry, T., Hassan, M. A., William, N. S., Yasser, V., Rashad, M. S., Tadres, K. E., & Mohyeldin, R. H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05688-w · Cited by 1
“N-acetylcysteine N-acetylcysteine (NAC), functioning as both a GSH precursor and a ROS scavenger, has been studied as an adjunct in DIPT and IPF; the IFIGENIA trial demonstrated that adding NAC to standard IPF therapy preserved lung function compared with standard care alone (Demedts et al. 2005).”
Pulmonary Fibrosis and Oxidative Stress
Kliment, C. R., & Oury, T. D. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0497-6_10 · Cited by 1
Vincent, P. K., Ahamed, H., Rajesh, G., Menon, R. N., & Venu, R. P. (2020) · Journal of Digestive Endoscopy · doi:10.1055/s-0040-1709791 · Cited by 1
Fahim, A. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13322 · Cited by 1
Clinical behaviour and mortality in idiopathic vs secondary nonspecific interstitial pneumonia
Wijayaratne, T., Owen, J., & Fahim, A. (2023) · Lung India · doi:10.4103/lungindia.lungindia_64_23 · Cited by 1
“[9] However, a subsequent multicenter randomized trial of triple therapy in comparison to placebo (PANTHER study) [10] found no benefit of immunosuppression in IPF and in fact, it was found to be detrimental so the approach was radically changed in early 2012 toward moving to antifibrotic therapy…”
ResultKu, C., Pan, J.-B., Wuputra, K., Hsu, W., Kato, K., Noguchi, M., Nakamura, Y., Saito, S., Tsai, C.-Y., Lin, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02262-2 · Cited by 2
Barne, M., Shevade, M., Bhattacharyya, P., Christopher, D. J., Nair, S., Abhyankar, N., Halder, I., Vora, A., Khanna, A., Swarnakar, R., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1810363 · Cited by 1
“Another retrospective study found better survival in UIP-type IPF with positive antinuclear antibody, possibly due to higher TOLLIP-TT prevalence (141).”
InfluentialSystemic Sclerosis: Severe Involvement of Internal Organs
Quillinan, N., & Denton, C. P. (2011) · Springer eBooks · doi:10.1007/978-0-85729-358-9_6 · Cited by 1
New Aspects of Idiopathic Pulmonary Fibrosis
Molina‐Molina, M., Vicens, V., & Estany, S. (2010) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3181e4bb22 · Cited by 1
“A large, randomized, double-blinded study, which compared efficacy of NAC, prednisone, azathioprine with prednisone, and azathioprine alone during 1 year demonstrated a significantly lower decline of lung function and little risk attributable to NAC.(47) However, the combination prednisone/azathioprine/NAC has not bee…”
BackgroundInfluentialTraitement des pneumopathies interstitielles diffuses
Cottin, V. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71669-2 · Cited by 2
Pneumopathies interstitielles diffuses
Cottin, V., & Crestani, B. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)74273-0 · Cited by 1
Rodriguez, E. C., Vargas, M. M. R., & Rivera, E. C. (2014) · Medicina Paliativa · doi:10.1016/j.medipa.2014.05.002 · Cited by 1
A Case of Progressive Lung Fibrosis
Fioret, D., Roman, J., Perez, R. L., & Perez, T. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821a9d52 · Cited by 1
Interstitielle Lungenerkrankungen: Differentialdiagnose und Therapie
Behr, J. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0613-z · Cited by 1
Self-citationDeux traitements efficaces pour la fibrose pulmonaire idiopathique : une nouvelle ère commence !
Crestani, B. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.05.011 · Cited by 1
Idiopathic interstitial pneumonias and immunologic diseases of the lungs
Hansell, D. M., Lynch, D. A., McAdams, H. P., & Bankier, A. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7234-3496-2.00015-4 · Cited by 1
Modulatory effect of D-pinitol on bleomycin-induced pulmonary fibrosis in rats
Duan, Y.-L., Wang, Z., Huo, Y.-X., Zhang, Y., Wu, X., Gong, C., & Bai, L. (2023) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.377407 · Cited by 1
Sherkawy, S., Elwakeel, L., Schaalan, M. F., Moharram, A., & Abouelwafa, M. Y. (2023) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2023.212265.1122 · Cited by 1
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Therapie der idiopathischen Lungenfibrose
Behr, J. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0607-x · Cited by 1
Self-citationCOPD-Exazerbation und Intensivtherapie
Koczulla, A. R., Greulich, T., Bals, R., & Vogelmeier, C. F. (2009) · Intensivmedizin und Notfallmedizin · doi:10.1007/s00390-009-0055-y · Cited by 1
Immunological Mechanisms and Clinical Aspects in Pulmonary- Renal Syndrome: A Review
Lukán, N. (2013) · InTech eBooks · doi:10.5772/55181 · Cited by 1
Perspectivas en el tratamiento de la fibrosis pulmonar idiopática
Morell, F., & Villar, A. (2012) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(12)70046-7 · Cited by 1
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Baroke, E., Maharaj, S. S., & Kolb, M. R. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.155 · Cited by 2
“57 Demedts M. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229–2242 (2005).”
Successful Treatment with Tacrolimus in a Case of Lung-dominant Connective Tissue Disease
Okamoto, M., Fujimoto, K., Nakamura, M., Yoshida, T., Idemoto, A., Kitasato, Y., Kawayama, T., Fukuoka, J., Ichiki, M., & Hoshino, T. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8867 · Cited by 1
Idiopathic Pulmonary Fibrosis: New Concept of Pathogenesis and Treatment
Uh, S. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.1.22 · Cited by 1
Pharmacotherapy in idiopathic pulmonary fibrosis
Acharya, G., Arya, S., Badal, S., Kumar, D., & Samdariya, S. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20141012 · Cited by 1
Nonobstructive Lung Disease and Thoracic Tumors
Pink, K., & Hope‐Gill, B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10050-9 · Cited by 1
Shohrati, M., Taheri, A., Borna, H., & Ghanei, M. (2016) · Journal of Advances in Medical and Pharmaceutical Sciences · doi:10.9734/jamps/2016/30622 · Cited by 1
“many different symptoms are relieved and QOL is improved [29-37].”
BackgroundThe Place Of Mucolytics In The treatment Of Inflammatory Respiratory Diseases
Kochuiev, G., Кочуева, М. Н., & Корж, А. Н. (2017) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2017.01.102 · Cited by 1
Diffuse parenchymal disease of the lung
CORRIN, B., & Nicholson, A. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3369-8.00006-9 · Cited by 1
Self-citationTraitement de la fibrose pulmonaire idiopathique
Valeyre, D., & Dion, G. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32328-3 · Cited by 1
Effect of N-acetylcystein on ERK Gene Expression in Ovarian Tissue of Acrylamide-Treated Adult Rats
NAİMİ, M., Shariati, M., Naeimi, S., & Edalatmanesh, M. A. (2020) · Jurnal Ilmu Ternak dan Veteriner · doi:10.14334/jitv.v25i1.2161 · Cited by 1
“Due to various pharmacological effects of NAC and its relative safety, the tendency to use it has increased in recent years (Demedts et al. 2005).”
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Focusing on idiopathic pulmonary fibrosis
Chaudhry, S. (2021) · Annals of Geriatric Education and Medical Sciences · doi:10.18231/j.agems.2020.013 · Cited by 1
Wells, A. U., & Хирани, Н. (2009) · PULMONOLOGIYA · doi:10.18093/0869-0189-2009-4-11-57 · Cited by 2
Pulmonary management of systemic sclerosis
Denton, C. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00141-x · Cited by 1
Bahoush, G., Rahab, M., & Ahmadvand, P. (2023) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2023.2292556 · Cited by 1
“13 Clinical studies comparing NAC to placebo have revealed minimal differences in adverse effects.”
BackgroundA pathophysiologic evaluation of the receptor for advanced glycation end products (RAGE) in the lung
Englert, J. M. (2009) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
van Schooten, F., Boots, A. W., Smolinska, A., & Dallinga, J. W. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0497-6_4 · Cited by 3
Bioengineering of Irradiated Normal Tissues by Bone Marrow Stem Cells
Greenberger, J. S., & Epperly, M. W. (2013) · Medical radiology · doi:10.1007/978-3-540-72314-1_13 · Cited by 1
Idiopathic pulmonary fibrosis : diagnosis, management, and the search for a cure.
Fioret, D. (2012) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/437 · Cited by 1
“However, in 2008, the Idiopathic Pulmonary Fibrosis International Group Exploring N-acetylcysteine I Annual Study tested the addition of an antioxidant, N-acety1cysteine, to the standard regimen [37].”
BackgroundMethodMolecular profiling of malignant pleural mesothelioma and pulmonary fibrosis
Lindholm, P. (2009) · Helda - University of Helsinki Institutional Repository · Cited by 1
Fluid Management in Acute Respiratory Distress Syndrome: A Step Forward
Martin, G. S. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208584.22679.8a · Cited by 1
Antioxidant therapy for idiopathic pulmonary fibrosis. A promising therapeutic prospect.
Tomioka, H. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 2
Triple terapia en fibrosis pulmonar idiopática
Castillo, D., & Barril, S. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.08.004 · Cited by 1
Pneumopathies interstitielles diffuses
Nunès, H. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)92793-x · Cited by 1
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.